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Abstract
Purpose In the USA, the burden of hepatitis B dispro-
portionately affects high-risk adults who alone account for
more than 75% of newly reported hepatitis B virus infec-
tions each year. Despite the localization of new infections
in identifiable high-risk groups, vaccination rates in this
subgroup, with the exception of health care workers,
remain consistently low. The purpose of this study was to
characterize those at risk for hepatitis B transmission and
quantify the association between missed opportunities and
hepatitis B vaccination.
Methods Data from the 2007 Behavioral Risk Factor
Surveillance Survey (BRFSS) of adults aged 18 years and
older who were at high risk for hepatitis B infection
(n = 15,432) were analyzed. Multivariate regression
analysis was conducted to determine factors independently
associated with vaccination.
Results In a nationally representative sample, 51.4% of
high-risk adults remained unvaccinated against hepatitis B
and more than 50% had a missed opportunity for vacci-
nation. High-risk adults who were vaccinated against
pneumonia and influenza had a higher odds ratio of being
vaccinated against hepatitis B than those not vaccinated
against pneumonia and influenza (OR 2.27 and 1.67,
respectively). Also, high-risk adults tested for human
immunodeficiency virus (HIV) at a counseling and testing
site or a drug treatment facility had a higher OR of being
vaccinated than those who had not been tested for HIV
(OR 1.78 and 1.73, respectively). The opposite relation-
ship was true among individuals tested for HIV at a cor-
rectional facility (OR 0.60).
Conclusions The findings of this study underscore the
inadequacy of vaccination coverage in high-risk adults and
highlight advantageous opportunities to bridge gaps in
vaccination coverage.
Keywords Hepatitis B virus  Vaccination  Prevention 
High-risk adults  Missed opportunities
Introduction
Hepatitis B has been a vaccine preventable illness since the
early 1980s. Yet, more than 1.25 million people in the USA
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are chronically infected with hepatitis B virus (HBV), and
every year almost 80,000 people become newly infected
with hepatitis B [1, 2]. Approximately 25% of those who
become chronically infected during childhood and 15% of
those who develop chronic infections after childhood die
prematurely of cirrhosis and/or hepatocellular carcinoma
[3]. In the USA and most industrialized countries, hepa-
titis B disproportionately affects high-risk adults, includ-
ing men who have sex with men, individuals with a
history of sexually transmitted diseases (STD) or multiple
sexual partners ([1 partner/6 months), incarcerated per-
sons, sex contacts of HBV-infected persons, health care
workers, and injection drug users. These groups alone
account for between 75 and 95% of newly reported
HBV infections each year [2, 3]. Despite the localization
of new infections in identifiable high-risk groups, vacci-
nation rates in these subsets of the population, with the
exception of health care workers, remain consistently low
and continuously fall short of national health objectives
[2, 3].
Since the hepatitis B vaccine first became available in
1982, great strides have been made in vaccinating infants,
children, and adolescents; however, very little progress has
been made in raising hepatitis B vaccine coverage in high-
risk adults. According to a national prevalence study using
National Health and Nutrition Examination Survey
(NHANES) data from 1999 to 2006, the burden of chronic
hepatitis B remains the greatest among adults and has
experienced little change in the past decade, despite vac-
cine availability and ostensible vaccine outreach [4].
Moreover, findings from a Centers of Disease Control and
Prevention (CDC) surveillance study conducted between
1998 and 2001 showed that [95% of an estimated 51,000
new infections in 2000 occurred in high-risk adults,
underscoring the inadequacy of vaccination coverage in
this population [3]. Surprisingly, of those newly infected,
[70% had a missed opportunity for vaccination in the
form of prior contacts with the health system or periods of
incarceration [5–7]. A study conducted among injection
drug users attending a STD clinic in San Diego between
1998 and 2001 found that vaccination coverage among
attendees was only 6%, highlighting the extent of missed
opportunities in this population [8].
The Institute of Medicine’s 2010 report on The National
Strategy for Prevention and Control of Hepatitis B and C
stressed the importance of capitalizing on opportunities to
vaccinate these individuals when they come into contact
with the health care system [9]. Previous literature has
posited that missed opportunities are largely attributable to
a lack of dedicated vaccination programs, understaffing
at facilities serving high-risk populations, and physi-
cian noncompliance with recommended guidelines for
the identification and vaccination of high-risk adults [9].
A better understanding of these potential areas of defi-
ciencies and predictors of immunization status is an
essential first step to improving uptake to vaccination in
high-risk populations.
The purpose of the study reported here was to quantify
the association between missed opportunities and identify
predictors for hepatitis B vaccine status among high-risk
adults. The study replicates a prior analysis performed
using the National Health Survey in 2000, adding addi-
tional information regarding access to care and sites of
contact with the health system and an assessment of what
progress has been made in addressing missed opportunities
since the last assessment. [5]. It is anticipated that this
study will provide insight to guide the development of
programs to meet the immunization recommendations
within the National strategy for prevention and control of
Hepatitis B and C.
Materials and methodology
Survey design and data collection
Data for this study were obtained from the 2007 Behavioral
Risk Factor Surveillance Survey (BRFSS) conducted by
the CDC. The BRFSS is an ongoing, nationwide telephone
survey system that has been tracking information on health
conditions and risk behaviors of the non-institutionalized
population in the USA annually since 1984 [10]. Data
collected from survey respondents are adjusted to represent
the population from which the sample is drawn. [11].
The questions of interest are a part of the BRFSS core
modules, and data are included from individuals from all
50 U.S. states, the District of Columbia, Puerto Rico, the
U.S. Virgin Islands, and Guam.
Participant selection
The population of interest consisted exclusively of adults
with behaviors that place them at high risk for hepatitis B
infection and for whom HBV vaccine status could be
specified. Operationally, adults were categorized as high
risk if they answered affirmatively to the following ques-
tion: ‘‘please tell me if any of these statements is true for
you. Do not tell me which statement or statements are true
for you, just if any of them are: you have hemophilia and
have received clotting factor concentrate; you have had sex
with a man who has had sex with other men, even just
one time; you have taken street drugs by needle, even just
one time; you traded sex for money or drugs, even
just one time; you have tested positive for human
406 F. Ladak et al.
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immunodeficiency virus (HIV); you have had sex (even
just one time) with someone who would answer ‘yes’ to
any of these statements; you had more than two sex part-
ners in the past year’’ [12] (n = 20, 431).
For the purposes of this study, individuals who
answered ‘‘Don’t know/not sure’’ or ‘‘Refused’’ to ques-
tions regarding high-risk behavior (n = 2,638) or hepa-
titis B vaccine status (n = 2,361) were excluded from the
analysis; this exclusion yielded an analytic sample of
15,432 respondents. Specific to the final model, individ-
uals who had missing data for a given predictor variable
were excluded only for that variable. The total number of
individuals excluded due to missing information on any
given predictor variable was 3,599 respondents (see
Fig. 1).
Variables of interest
Outcome variable
The study’s primary outcome variable was hepatitis B
vaccine status. Operationally, vaccine status for a high-risk
adult was specified by their answer to the following
question: ‘‘have you ever received the hepatitis B vaccine?
The hepatitis B vaccine is completed after the third shot is
given’’ [12]. An affirmative answer to this question indi-
cates that the respondent had completed the entire hepatitis
B vaccine series.
Predictor variables
Predictor variables considered in the analysis were cate-
gorized as demographic variables, access to health care
variables, and health care utilization variables.
Sex, race, relationship status, income, age, and educa-
tional level were included among the demographic vari-
ables. Sex, race, income, and educational level were
operationalized using the definitions specified by the
BRFSS (see Table 1). These variables have previously
been used to characterize high-risk adults and have yielded
inconclusive evidence regarding their strength as predictors
of hepatitis B vaccine status [5]. Relationship status was
created from the original field ‘‘marital status’’ by dichot-
omizing the original fields into ‘‘in a relationship’’
(‘‘married’’ or ‘‘member of an unmarried couple’’) and ‘‘not
in a relationship’’ (‘‘divorced’’, ‘‘widowed’’, ‘‘single’’ or
‘‘separated’’) to reflect both the extent of social support and
the risk of acquisition or transmission of hepatitis B
through sexual activity. Age was also redefined in order to
distinguish between individuals who were eligible for
catch-up vaccines at the time of the study and those who
were not. The new categories included ‘‘18–33 years’’ and
‘‘older than 33 years of age’’.
Variables included under access to health care collec-
tively corresponded to barriers to establishing contact with
the health care system, including health insurance status
(‘‘insured’’ or ‘‘uninsured’’), established source of primary
Fig. 1 Participant selection:
illustration of the selection
procedure of participants
eligible for inclusion in the
study. BRFSS Behavioral Risk
Factor Surveillance Survey
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Table 1 Demographic, health care access, and health care utilization variables among high-risk adults, aged 18 years and older
Potential predictors Vaccinated
against hepatitis
B (n = 6,770; 44%)
Not vaccinated
against hepatitis
B (n = 8,662; 56%)
p value for
heterogeneity
Demographics
Sex
Male 47% (n = 3,331) 53% (n = 4,924) 0.01
Female 52% (n = 3,439) 48% (n = 3,738)
Race
Hispanic 46% (n = 592) 54% (n = 655) 0.68
White 48% (n = 4,632) 52% (n = 6,258)
Black or African American 52% (n = 948) 48% (n = 1,043)
Asian 49% (n = 85) 51% (n = 77)
Native Hawaiian or Pacific Islander 52% (n = 20) 48% (n = 35)
American Indian or Alaskan Native 58% (n = 170) 42% (n = 178)
Other 46% (n = 73) 54% (n = 95)
Multiracial 53% (n = 207) 47% (n = 222)
Relationship status
In a relationship (married, a member of an unmarried couple) 44% (n = 1,465) 56% (n = 1,974) \0.01
Not in a relationship (single, divorced, widowed, separated) 51% (n = 1,465) 49% (n = 2,469)
Income
Less than $10,000 44% (n = 500) 56% (n = 751) 0.05
Less than $15,000 44% (n = 402) 56% (n = 663)
Less than $20,000 45% (n = 538) 55% (n = 714)
Less than $25,000 48% (n = 666) 52% (n = 800)
Less than $35,000 48% (n = 809) 52% (n = 1,041)
Less than $50,000 45% (n = 942) 55% (n = 1,251)
Less than $75,000 50% (n = 913) 50% (n = 1,180)
More than $75,000 51% (n = 1,419) 49% (n = 1,511)
Age (years)
18–33 61% (n = 1,374) 39% (n = 587) \0.01
Older than 33 36% (n = 1,509) 64% (n = 1,243)
Education
Never attended school or only attended kindergarten 40% (n = 15) 60% (n = 15) 0.01
Elementary (Grade 1 through 8) 32% (n = 98) 68% (n = 320)
Some high school (Grade 9 through 11) 44% (n = 524) 56% (n = 802)
High school graduate (Grade 12 or GED) 47% (n = 1,741) 53% (n = 2,592)
Some college or technical school (College 1 year to 3 years) 52% (n = 2,115) 48% (n = 2,345)
College graduate (College 4 years or more) 51% (n = 2,271) 49% (n = 2,563)
Access to health care
Health insurance coverage
Insured 51% (n = 1,365) 49% (n = 2,019) \0.01
Uninsured 43% (n = 5,372) 57% (n = 6,620)
Regular provider
No 46% (n = 1,530) 54% (n = 2,173) 0.12
Yes, only one 50% (n = 4,643) 50% (n = 5,760)
Yes, more than one 46% (n = 574) 54% (n = 707)
Could not see a doctor because of cost
No 50% (n = 5,243) 50% (n = 6,531) \0.01
Yes 43% (n = 1,521) 57% (n = 2,107)
408 F. Ladak et al.
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care (‘‘no’’, ‘‘yes, only one’’, and ‘‘yes, more than one’’), and
cited financial barrier to necessary care (‘‘yes’’ or ‘‘no’’).
Finally, variables that reflected points of contact with
the health care system or health care utilization, included
recency of last routine checkup (‘‘never’’, ‘‘within the last
year’’, ‘‘within the past 2 years’’, ‘‘within the past 5 years’’,
‘‘5 years or more’’), a vaccination against influenza in the
past 12 months, ever being vaccinated against pneumonia,
and HIV testing status and location (‘‘never tested’’, ‘‘pri-
vate doctor/health maintenance organization (HMO)’’,
‘‘counseling or testing site’’, ‘‘hospital’’, ‘‘clinic’’, ‘‘jail/
prison/correctional facility’’, ‘‘drug treatment facility’’,
‘‘home’’, ‘‘somewhere else’’) were considered as potential
missed opportunities.
Statistical analysis
The STATA statistical software program version 10 was
used for all analyses [13]. Survey commands were used to
account for sampling weights and to obtain standard
errors that take complex survey designs into consider-
ation. Weighted proportions were used to describe the
distribution of demographic characteristics with respect to
vaccine status. Potential predictors for vaccine receipt
among high-risk adults were first analyzed univariately
using the chi-square statistic for homogeneity across pro-
portions. Variables with a p value of\0.25 were considered
for inclusion into the final logistic model. The relationship
between multiple covariates and the outcome was assessed
using backward-selection multivariate logistic regression.
Covariates with at least one coefficient significant at a
p value of B0.05 were retained in the model. Weak pre-
dictors (p value between 0.05 and 0.25) with a significant
theoretical potential for confounding were also retained. A
weak predictor was considered to be a confounder if it
changed any coefficient by at least 10%. Estimates of
association between potential predictors and hepatitis B
vaccine status were calculated using odds ratios (ORs).
Sensitivity analysis was performed to determine if
individuals with missing information with regard to hepa-
titis B immunization status differed significantly from
those with information on vaccine status. This was done by
repeating the analysis first with individuals with missing
hepatitis B immunization status coded as immunized and
Table 1 continued
Potential predictors Vaccinated
against hepatitis
B (n = 6,770; 44%)
Not vaccinated
against hepatitis
B (n = 8,662; 56%)
p value for
heterogeneity
Health care utilization
Last time you had a routine check-up
Never 39% (n = 68) 61% (n = 159) \0.01
Within the past year 52% (n = 4,350) 48% (n = 5,125)
Within the past 2 years 49% (n = 1,039) 51% (n = 1,207)
Within the past 5 years 51% (n = 702) 49% (n = 915)
5 years or more 32% (n = 542) 68% (n = 1,097)
Influenza vaccine in past 12 months
No 45% (n = 4,188) 55% (n = 6,089) \0.01
Yes 57% (n = 2,541) 43% (n = 2,543)
Ever had a pneumonia vaccine
No 44% (n = 4,169) 56% (n = 6,386) \0.01
Yes 61% (n = 1,682) 39% (n = 1,555)
Location of HIV testing
Not tested 56% (n = 2,764) 44% (n = 1,654) \0.01
Private doctor or HMO 66% (n = 1,805) 34% (n = 1,748)
Counseling or testing site 50% (n = 248) 50% (n = 272)
Hospital 63% (n = 729) 37% (n = 672)
Clinic 51% (n = 1,233) 49% (n = 1,273)
Jail or prison or other correctional facility 29% (n = 89) 71% (n = 144)
Drug treatment facility 44% (n = 57) 56% (n = 64)
At home 30% (n = 61) 70% (n = 113)
Somewhere else 62% (n = 324) 38% (n = 259)
HIV, Human immunodeficiency virus; HMO, health maintenance organization
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then with those with individuals coded as eligible for
immunization. If the conclusions were not altered by
assigning all missing observations to immunized or not
(worst case scenario), then the observed relationships were
considered to be robust.
Results
Among high-risk respondents (20,431 adults ages 18 years
and older), information regarding hepatitis B vaccine status
was available for 15,432 respondents, of whom 6,770 (44%)
reported being vaccinated against hepatitis B and 8,662
(56%) reported being unvaccinated against hepatitis B.
Results from the univariate analysis (Table 1) indicate
that the proportion of high-risk adults vaccinated against
hepatitis B compared to those who were not vaccinated
against hepatitis B varied significantly by relationship
status, age, health insurance status, cost as cited barrier to
needed care, influenza and pneumonia vaccine receipt, and
HIV testing location status (p \ 0.01).
In this cohort, a greater percentage of individuals who
were aged 18–33 years (those eligible for catch-up vacci-
nation) reported being vaccinated against hepatitis B (61%)
in comparison to adults older than 33 (36%). Conversely, a
smaller percentage of individuals who reported being in a
relationship were vaccinated against hepatitis B (44%) in
comparison to those who reported not being in a relationship
(51%). In addition to being statistically significantly differ-
ent by vaccination status, age and relationship status were
also identified as confounders. As such, they were accounted
for in the final adjusted logistic regression model (Table 2).
In terms of health care utilization, a greater percentage
of individuals with prior receipt of either the influenza or
pneumonia vaccine (57 and 61%, respectively) reported
being vaccinated against hepatitis B in comparison to those
who had not been immunized against either influenza or
pneumonia (45 and 44%, respectively). When HIV testing
location was stratified by hepatitis B vaccine status, a
smaller percentage of individuals who had been tested for
HIV at a jail/prison/correctional facility or a drug treatment
facility reported being vaccinated against hepatitis B (29
and 44%, respectively) in comparison to individuals who
had been tested for HIV at a private doctor/HMO, hospital,
clinic, or counseling and testing site (66, 63, 51, and 50%,
respectively).
Predictors of hepatitis B vaccine coverage in high-risk
adults
When other predictors in the model were controlled for,
high-risk adults who were vaccinated against pneumonia
and influenza had an increased OR of being vaccinated
against hepatitis B compared to those who had not vacci-
nated against pneumonia and influenza [OR 2.27, 95%
confidence interval (CI) 1.80–2.87) and OR 1.68, 95% CI
1.39–2.03, respectively). Similarly, individuals with health
insurance had a higher OR of being vaccinated against
hepatitis B than those without insurance (OR 1.39, 95% CI
1.08–1.80). By contrast, individuals who reported being
unable to see a doctor because of cost had a lower OR of
being vaccinated against hepatitis B (OR 0.77, 95% CI
0.60–0.98).
Lastly, HIV testing location was an important predictor
of hepatitis B vaccine status. High-risk adults who had
been tested for HIV at a private doctor’s office or HMO, a
counseling and testing site, a hospital, a clinic, a drug
treatment facility, or somewhere else had a higher OR of
Table 2 Potential predictors for hepatitis B vaccine receipt among
high-risk adults
Predictors for
vaccine status
Adjusted odds ratio
(95% confidence interval)
Ever had a pneumonia shot
No 1.00 (reference)
Yes 2.27 (1.80–2.87)
Influenza vaccine in the past 12 months
No 1.00 (reference)
Yes 1.67 (1.38–2.03)
Location of HIV testing
Not tested 1.00 (reference)
Somewhere else 2.12 (1.29–3.50)
Private doctor or HMO 1.89 (1.47–2.41)
Counseling and testing site 1.78 (0.93–3.45)
Hospital 1.54 (1.17–2.04)
Clinic 1.35 (1.03–1.76)
Jail or prison 0.60 (0.33–1.08)
Drug treatment facility 1.73 (0.64–4.68)
At home 1.08 (0.60–1.95)
Health Insurance status
Uninsured 1.00 (reference)
Insured 1.39 (1.08–1.79)
Age (eligible for catch-up vaccination)
18–33 years 1.00 (reference)
Older than 33 years 0.33 (0.27–0.40)
Relationship status
Not in a relationship 1.00 (reference)
In a relationship 1.21 (1.00–1.45)
Could not see a doctor because of cost
No 1.00 (reference)
Yes 0.77 (0.60–0.98)
Sex
Male 1.00 (reference)
Female 0.84 (0.70–1.01)
410 F. Ladak et al.
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being vaccinated than those who had not been tested for
HIV (OR 1.88, 95% CI 1.47–2.41; OR 1.79, 95% CI
0.93–3.41; OR 1.54, 95% CI 1.17–2.04; OR 1.34, 95% CI
1.03–1.76; OR 1.74, 95% CI 0.64–4.68; OR 2.12, 95%
CI 1.29–3.50, respectively). The opposite relationship was
true among individuals tested for HIV at a correctional
facility (OR 0.60, 95% CI 0.33–1.07). However, associa-
tions observed between hepatitis B vaccine receipt and
HIV testing at a testing and counseling site, a drug treat-
ment facility, and jails/correctional facilities were not sig-
nificant, possibly partially reflecting the fact that the total
number of people who reported being tested at these sites
was low (n = 526, 233, and 121, respectively). A strong
relationship between being tested in other unclassified
settings (reported as ‘‘somewhere else’’) was observed
despite comparably low sample sizes (n = 583), thereby
reflecting the strength of the identified association.
Sex was a weak predictor (p = 0.061) but was retained
in the model due to the potential impact it has on patterns
of health care utilization.
Sensitivity analysis conducted on individuals with
missing information with regard to hepatitis B vaccine
status indicated that the observed conclusions were not
altered when extreme values were assumed for the missing
data.
Discussion
This study provides a nationally representative estimate for
hepatitis B vaccine coverage among high-risk adults
(C18 years of age) in the USA. The 2007 BRFSS data
indicate that receipt of the complete hepatitis B vaccine
series continues to be low in this population, with over half
of respondents reporting that they were never vaccinated
against hepatitis B (56.13%). Consistent with past research,
missed opportunities were frequent in this population,
particularly among those adults who reported being tested
for HIV at jails or correctional facilities (71%). Other
factors that were significantly associated with completing
the hepatitis B vaccine series included receipt of previous
vaccines (pneumonia and influenza), health insurance sta-
tus, prohibitive costs associated with seeing a doctor, age
group, sex, and being in a relationship. The increased
likelihood of hepatitis B vaccine receipt observed among
adults 18–33 years of age likely reflects policy amend-
ments made in the early 1990s, which universalized
hepatitis B vaccination at birth in the USA and initiated
catch-up vaccination programs for children and adoles-
cents. Past studies, both domestically in Alaska as well as
internationally, have documented similar distributions in
hepatitis B vaccine receipt, where younger adults were
more likely to have been vaccinated due to catch-up
vaccination programs than older adults [14, 15]. The
associations between sex and relationship status may
reflect previously documented increased utilization of
health services by women and by those in relationships [16,
17].
Previous receipt of other vaccines was an independent
predictor of hepatitis B vaccine status, where adults who
reported prior receipt of immunizations against pneumonia
and/or influenza also had a greater OR of being vaccinated
against hepatitis B. This association could be a reflection of
provider or patient practices [18]. Since chronic liver dis-
ease due to causes other than hepatitis B is indicator for
influenza and pneumonia vaccination, one may expect a
significant correlation—at least amongst this subgroup [5].
Alternatively, one could posit that patients who reported
receiving the influenza and/or pneumonia vaccine have a
heightened awareness of the utility and importance of
vaccines in disease prevention and therefore were more
likely to accept or request a vaccine against hepatitis B
[19].
By contrast, individuals who reported being uninsured
were less likely to be vaccinated against hepatitis B. This
finding is not unexpected given the paucity of federal
public funds allocated to purchasing vaccines for the
uninsured adult population in the USA and the often
suboptimal coverage for adult vaccines under private
insurance plans [20, 21]. In 2005, a total of only 4.5% of
the $234,897,000 funds appropriated for the purchase of
vaccines was used for adult populations, yielding a
funding shortfall of approximately $160 million [20]. This
translates into a substantial proportion of uninsured adults
being unable to access recommended immunization ser-
vices through federally funded vaccination programs.
Without health insurance, each dose of the hepatitis B
vaccine can cost up to $100.00, including the fee for
administration [22]. For individuals with government-
sponsored insurance (Medicaid), the fee for vaccination is
between $0.50 and $6.00 for each hepatitis B vaccine,
depending on the U.S. state of residence [23]. However,
strict eligibility criteria for medicaid may prevent a large
proportion of high-risk adults from benefiting from sub-
sidized vaccination rates. As a result, high costs associ-
ated with this vaccine may discourage uptake in this
population. This may explain, in part, why immunization
rates have remained consistently low among uninsured
high-risk adults.
In addition to inadequate insurance coverage for hepa-
titis B vaccination, low rates of vaccination, even amongst
the insured may indicate poor levels of physician adher-
ence to clinical practice guidelines. In a 2007 review by
Cabana et al. [26] and a 2009 national survey that specif-
ically addressed provider adherence to hepatitis B guide-
lines, external barriers, including lack of a reminder
Hepatitis B in the United States 411
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system, lack of counseling materials, insufficient staff or
consultant support, poor reimbursement, increased practice
costs, and increased liability, were found to undermine
physician adherence to established guidelines, even among
physicians with an awareness of and familiarity with
clinical guidelines [24–26]. Their findings suggest that low
levels of physician adherence may reflect broader resource
limitations and structural problems in the financing of
health care. Thus, in order for physician care visits to be an
effective point of delivery for immunization services,
concerns regarding resource constraints and inadequate
reimbursement for vaccinating under- and uninsured pop-
ulations need to be addressed.
Finally, missed opportunities for hepatitis B vaccination
continue to occur in vaccine delivery settings frequented by
high-risk adults, such as prisons and jails, drug treatment
centers, and HIV counseling and testing sites. The impor-
tance of capitalizing on contacts with the health care sys-
tem to improve hepatitis B vaccine coverage is stressed in
both the 2006 comprehensive immunization strategy to
eliminate transmission of hepatitis B virus in the USA
issued by the CDC and the 2010 Institute of Medicine
(IOM) report on the ‘‘national strategy for prevention and
control of hepatitis B and C’’ [3, 9]. In the IOM report,
committee members place special emphasis on eradicating
missed opportunities for hepatitis B vaccine receipt, par-
ticularly in facilities such as prisons and jails, STD clinics,
and drug treatment centers that experience high rates of
recidivism and a high degree of overlap in persons seen at
these locations [2, 9]. The routine use of standing orders
and targeted education has been recommended as a means
of improving vaccination coverage in these settings; how-
ever, perpetual underfunding and understaffing limits the
ability of immunization programs to implement these
strategies [2, 3]. Scarcity of funding and systematic vac-
cination of high-risk adults when they come into contact
with the health care system are collectively addressed in
the recommendations issued by the IOM (Table 3).
Our findings confirm the inadequacy of vaccine service
provision at the key care access points highlighted in the
IOM report. Among all locations assessed, individuals who
received their HIV testing at correctional facilities were the
least likely to be vaccinated against hepatitis B in com-
parison to those who had not been tested for HIV. This
finding is of great concern in light of that fact that at least
20 U.S. states have mandated hepatitis B vaccination of all
incarcerated populations [9]. Future research should assess
the effectiveness of state prison mandates in a stratified
analysis of vaccine receipt in U.S. states with and without
vaccine mandates.
Limitations
There are several important limitations to this study. First, the
BRFSS relies on self-reported data. As such, it is impossible
to assess the accuracy of information provided about an
individual’s immunization history. Second, the BRFSS asks
participants to respond affirmatively to ‘‘Have you ever been
vaccinated against hepatitis?’’ only if they have completed
the vaccine series. This excludes valuable information about
individuals who may be in the course of completing the
vaccine series or who may have received immunity from a
partial series in the past. Though the response may not be as
durable, one dose confers immunity in 55% of those tested,
and two doses confers immunity in 85% of those tested [2, 9].
Third, the multi-component BRFSS question on high-risk
behavior does not allow for determination of whether vac-
cination coverage differs within distinct subgroups of high-
risk adults. Fourth, the multi-component question about HIV
testing locations did not specify the types of clinics included
under the category ‘‘clinics’’. Individual interpretation of the
word ‘‘clinic’’ may vary. For some respondents a clinic could
mean a free clinic, needle-exchange, STD, or simply a walk-
in clinic that does not require that everyone be an established
patient. This also limits the ability to target interventions
based on the observed low vaccination rates in this group.
Conclusions
The results of this study, in combination with recommen-
dations issued by the IOM, underscore the inadequacy of
Table 3 Recommendation 4-3 from the 2010 Institute of Medicine report—additional federal and state resources should be devoted to
increasing hepatitis B vaccination of at-risk adults
Correctional institutions should offer hepatitis B vaccination to all incarcerated persons
Accelerated schedules for vaccine administration should be considered for jail inmates
Organizations that serve high-risk people should offer the hepatitis B vaccination series
Efforts should be made to improve identification of at-risk adults
Health care providers should routinely seek risk histories from adult patients through direct questioning and self assessment
Efforts should be made to increase rates of completion of the vaccine series in adults
Federal and state agencies should determine gaps in hepatitis B vaccine coverage among at-risk adults annually and estimate the resources
needed to fill the gaps
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vaccination coverage in high-risk adults and highlight areas
of opportunity to bridge gaps in vaccination coverage.
Locations serving high-risk populations need to be made
key partners in the national effort to reduce hepatitis B
transmission. A significant part of this effort will involve
collaboration with such facilities to determine and address
deficits in human resources, organizational capacity, vac-
cine availability, and reimbursement that limit systematic
vaccination of high-risk adults. Given burgeoning ranks of
the uninsured and underinsured, support for programs
through U.S. state and local departments of health that
provide vaccines to at-risk populations will be critical. By
working together to address these barriers, immunization
uptake among high-risk adults can be markedly improved,
in turn diminishing the burden of hepatitis B disease in the
USA.
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